Home » Biodefense Market
Biodefense Market
Published date: Nov 2021 •Formats:
Request Sample Schedule a Call

Global Biodefense Market By Product (Anthrax, Botulism, Smallpox, Nuclear/Radiation, and Other Products), By Application (Civilian, and Military), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

  • Published date: Nov 2021
  • Report ID: 21643
  • Number of Pages: 302
  • Format:
  • keyboard_arrow_up
      • 1. Biodefense Market Introduction
        • 1.1. Definition
        • 1.2. Taxonomy
        • 1.3. Research Scope
      • 2. Executive Summary
        • 2.1. Key Findings by Major Segments
        • 2.2. Top strategies by Major Players
      • 3. Global Biodefense Market Overview
        • 3.1. Biodefense Market Dynamics
          • 3.1.1. Drivers
          • 3.1.2. Opportunities
          • 3.1.3. Restraints
          • 3.1.4. Challenges
        • 3.2. PESTLE Analysis
        • 3.3. Opportunity Map Analysis
        • 3.4. PORTER'S Five Forces Analysis
        • 3.5. Market Competition Scenario Analysis
        • 3.6. Product Life Cycle Analysis
        • 3.7. Opportunity Orbits
        • 3.8. Manufacturer Intensity Map
      • 4. Global Biodefense Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
        • 4.1. Global Biodefense Market Analysis by Type: Introduction
        • 4.2. Market Size and Forecast by Region
        • 4.3. Anthrax
        • 4.4. Smallpox
        • 4.5. Botulism
        • 4.6. Radiation/Nuclear
      • 5. Global Biodefense Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
        • 5.1. Global Biodefense Market Analysis by Application: Introduction
        • 5.2. Market Size and Forecast by Region
        • 5.3. US Military Market
        • 5.4. US Civilian Market
        • 5.5. Non-US Market
      • 6. Global Biodefense Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
        • 6.1. North America
          • 6.1.1. North America Biodefense Market: Regional Trend Analysis
            • 6.1.1.1. US
            • 6.1.1.2. Canada
            • 6.1.1.3. Mexico
        • 6.2. Europe
          • 6.2.1. Europe Biodefense Market: Regional Trend Analysis
            • 6.2.1.1. Germany
            • 6.2.1.2. France
            • 6.2.1.3. UK
            • 6.2.1.4. Russia
            • 6.2.1.5. Italy
            • 6.2.1.6. Rest of Europe
        • 6.3. Asia-Pacific
          • 6.3.1. Asia-Pacific Biodefense Market: Regional Trend Analysis
            • 6.3.1.1. China
            • 6.3.1.2. Japan
            • 6.3.1.3. Korea
            • 6.3.1.4. India
            • 6.3.1.5. Rest of Asia
        • 6.4. Latin America
          • 6.4.1. Latin America Biodefense Market: Regional Trend Analysis
            • 6.4.1.1. Brazil
            • 6.4.1.2. Argentina
            • 6.4.1.3. Rest of Latin America
        • 6.5. Middle East and Africa
          • 6.5.1. Middle East and Africa Biodefense Market: Regional Trend Analysis
            • 6.5.1.1. GCC
            • 6.5.1.2. South Africa
            • 6.5.1.3. Israel
            • 6.5.1.4. Rest of MEA
      • 7. Global Biodefense Market Competitive Landscape, Market Share Analysis, and Company Profiles
        • 7.1. Market Share Analysis
        • 7.2. Company Profiles
        • 7.3. Emergent Biosolutions
          • 7.3.1. Company Overview
          • 7.3.2. Financial Highlights
          • 7.3.3. Product Portfolio
          • 7.3.4. SWOT Analysis
          • 7.3.5. Key Strategies and Developments
        • 7.4. Hytest
          • 7.4.1. Company Overview
          • 7.4.2. Financial Highlights
          • 7.4.3. Product Portfolio
          • 7.4.4. SWOT Analysis
          • 7.4.5. Key Strategies and Developments
        • 7.5. GSK
          • 7.5.1. Company Overview
          • 7.5.2. Financial Highlights
          • 7.5.3. Product Portfolio
          • 7.5.4. SWOT Analysis
          • 7.5.5. Key Strategies and Developments
        • 7.6. Sanofi
          • 7.6.1. Company Overview
          • 7.6.2. Financial Highlights
          • 7.6.3. Product Portfolio
          • 7.6.4. SWOT Analysis
          • 7.6.5. Key Strategies and Developments
        • 7.7. PharmAthene
          • 7.7.1. Company Overview
          • 7.7.2. Financial Highlights
          • 7.7.3. Product Portfolio
          • 7.7.4. SWOT Analysis
          • 7.7.5. Key Strategies and Developments
        • 7.8. Bavarian Nordic
          • 7.8.1. Company Overview
          • 7.8.2. Financial Highlights
          • 7.8.3. Product Portfolio
          • 7.8.4. SWOT Analysis
          • 7.8.5. Key Strategies and Developments
        • 7.9. SIGA Technologies
          • 7.9.1. Company Overview
          • 7.9.2. Financial Highlights
          • 7.9.3. Product Portfolio
          • 7.9.4. SWOT Analysis
          • 7.9.5. Key Strategies and Developments
        • 7.10. Arbutus Biopharma
          • 7.10.1. Company Overview
          • 7.10.2. Financial Highlights
          • 7.10.3. Product Portfolio
          • 7.10.4. SWOT Analysis
          • 7.10.5. Key Strategies and Developments
        • 7.11. DynPort Vaccine
          • 7.11.1. Company Overview
          • 7.11.2. Financial Highlights
          • 7.11.3. Product Portfolio
          • 7.11.4. SWOT Analysis
          • 7.11.5. Key Strategies and Developments
        • 7.12. Xoma Corporation
          • 7.12.1. Company Overview
          • 7.12.2. Financial Highlights
          • 7.12.3. Product Portfolio
          • 7.12.4. SWOT Analysis
          • 7.12.5. Key Strategies and Developments
        • 7.13. Ichor Medical Systems
          • 7.13.1. Company Overview
          • 7.13.2. Financial Highlights
          • 7.13.3. Product Portfolio
          • 7.13.4. SWOT Analysis
          • 7.13.5. Key Strategies and Developments
        • 7.14. Aeolus Pharmaceuticals
          • 7.14.1. Company Overview
          • 7.14.2. Financial Highlights
          • 7.14.3. Product Portfolio
          • 7.14.4. SWOT Analysis
          • 7.14.5. Key Strategies and Developments
        • 7.15. Achaogen
          • 7.15.1. Company Overview
          • 7.15.2. Financial Highlights
          • 7.15.3. Product Portfolio
          • 7.15.4. SWOT Analysis
          • 7.15.5. Key Strategies and Developments
        • 7.16. Elusys Therapeutics
          • 7.16.1. Company Overview
          • 7.16.2. Financial Highlights
          • 7.16.3. Product Portfolio
          • 7.16.4. SWOT Analysis
          • 7.16.5. Key Strategies and Developments
        • 7.17. Dynavax Technologies
          • 7.17.1. Company Overview
          • 7.17.2. Financial Highlights
          • 7.17.3. Product Portfolio
          • 7.17.4. SWOT Analysis
          • 7.17.5. Key Strategies and Developments
        • 7.18. Cleveland BioLabs
          • 7.18.1. Company Overview
          • 7.18.2. Financial Highlights
          • 7.18.3. Product Portfolio
          • 7.18.4. SWOT Analysis
          • 7.18.5. Key Strategies and Developments
        • 7.19. Soligenix
          • 7.19.1. Company Overview
          • 7.19.2. Financial Highlights
          • 7.19.3. Product Portfolio
          • 7.19.4. SWOT Analysis
          • 7.19.5. Key Strategies and Developments
        • 7.20. Alnylam Pharmaceuticals
          • 7.20.1. Company Overview
          • 7.20.2. Financial Highlights
          • 7.20.3. Product Portfolio
          • 7.20.4. SWOT Analysis
          • 7.20.5. Key Strategies and Developments
        • 8. Assumptions and Acronyms
        • 9. Research Methodology
        • 10. Contact
    • XOMA corporation
    • Emergent Bio Solutions Inc.
    • SIGA Technologies.
    • Ichor Medical Systems.
    • Elusys Therapeutics Inc.
    • Dynavax Technologies Corporation.
    • Altimmune Inc.
    • Bavarian Nordic.
    • Other Key Players
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Biodefense Market
  • 21643
  • Nov 2021
    • ★★★★★
      ★★★★★
    • (53)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
auto undefined
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sundanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
Find Help
Legal
Explore